Clinical trials

#Biotherapeutics #Clinical trials #Drug discovery #Life sciences

Awakn Life Sciences: new CRO and patent application

Awakn Life Sciences has appointed neuroscientist and addiction researcher, Professor David Nutt as Chief Research Officer as well as announcing the filing of patent applications in the US for two next-generation novel MDMA-derived new chemical entities. This executive appointment is driven by the expansion of Awakn’s psychedelic drug and therapy… Read More

#News

Eye
#Biotechnology #Clinical trials #Drug development #Drug discovery #Stem cells

Dry Eye Syndrome drug candidate shows promise

BRIM Biotechnology has announced it is preparing to initiate Phase III trials in 2022 for BRIM421. BRIM421 is a first-in-class peptide derived from BRIM’s proprietary, stem cell regenerative, Short Peptide (PDSP) technology platform, which can also be applied across multiple therapy areas and indications. Data demonstrate the drug has the… Read More

#News

#Cancer research #Clinical trials #Immunotherapy #Oncology #Pharmaceuticals

Unlocking the potential for autologous vaccines

In the last decade, cancer immunotherapy has emerged as one the most promising treatments for the disease. In a recent pilot study, Professor Joachim Drevs and his co-authors; Joachim Ahlers, Eglys Gonzalez Marcano and Leona Kröhle describe how a new autologous vaccine developed in partnership with cancer clinic RGCC created… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News #Opinion

#Biotherapeutics #Cancer research #CAR-T #Cell therapy #Clinical trials #Drug development

Aleta and Cancer Research UK to advance blood cancer therapy

Aleta Biotherapeutics and Cancer Research UK have collaborated to advance the early phase clinical development of Aleta’s CAR-T cell engager candidate, ALETA-001. Under the terms of the clinical development partnership, Cancer Research UK’s Centre for Drug Development will fund, sponsor and conduct the first-in-human Phase I/IIa clinical trial of ALETA-001,… Read More

#News

#Biotechnology #Clinical trials #Data

Formedix and CDISC join forces to accelerate clinical trial set-up

Formedix, a provider of clinical trial software solutions, has collaborated with CDISC, the global clinical research data standards development organisation, to create a novel portal providing free access to ready-to-use, CDASH-compliant, annotated electronic case report forms (eCRFs). As part of this partnership, Formedix’s all-in-one cloud-based clinical metadata repository (CMDR) and… Read More

#News

#AstraZeneca #Cancer research #Clinical trials #Institute of Cancer Research

First medicine approved in the EU to treat rare genetic condition

AstraZeneca and MSD’s Koselugo (selumetinib) has been granted conditional approval in the European Union for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged three years and above. NF1 is a debilitating genetic condition affecting one in 3,000 individuals worldwide. In 30-50%… Read More

#News

#AstraZeneca #Biologics / Biotechnology #Clinical trials #Drug delivery #Drug development #Pharma

Chinese/Western partnership to promote indigenous drugs

Chinese biopharma companies are eyeing strategic collaborations with Western counterparts to leverage their networks and commercial capabilities to promote indigenously developed drugs in China, says GlobalData, a data and analytics company. China-based Luye Pharma Group’s holding subsidiary Boan Biotech signed an agreement with AstraZeneca China in May 2021 regarding the… Read More

#Market Reports #News #Trends & Analysis

#Clinical trials #Covid-19 #CureVac #Immunology / Virology & Vaccines

CureVac mRNA vaccine only 47% effective

CureVac has announced results of the second interim analysis of its international pivotal Phase IIb/III study in approximatively 40,000 subjects (the HERALD study) of CureVac’s first-generation Covid-19 vaccine candidate, CVnCoV. At second interim analysis, statistical success criteria were not met. In the unprecedented context of at least 13 variants circulating… Read More

#Covid-19 #News #Trending News

#Clinical trials #Drug development #Drug screening #Screening

Sygnature Discovery expands into early CMC development

Sygnature Discovery has announced the set-up of an Early Candidate Developability Screening Group. Located at its headquarters in Nottingham, UK, the new service line will expand on the company’s offerings to customers by bridging into formal preclinical drug development and paving the way for clinical trials. With over £1 million… Read More

#News

#Clinical trials #Covid-19 #Data #GlobalData #Immunology / Virology & Vaccines

Covid-19 vaccine and therapeutic trials show different trends

Since Covid-19 was officially declared a pandemic by the World Health Organization (WHO), the peak in total number of clinical trials for the virus was seen in the month of April 2020. There has since been a steady decrease in new clinical trial investigations, except for the months of December… Read More

#News #Trends & Analysis

#Clinical trials #Covid-19 #Drug delivery #Drug development #Immunology / Virology & Vaccines #Johnson & Johnson #Vaccines

Janssen single-dose COVID-19 vaccine approved for use in the UK

Johnson & Johnson has announced topline efficacy and safety data from the Phase III ENSEMBLE clinical trial, demonstrating that the investigational single-dose Covid-19 vaccine in development at Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468… Read More

#Covid-19 #News #Trending News

#Biologics #Clinical trials #Crohn's disease

Study of biologic therapies for moderate to severe Crohn’s Disease

The Janssen Pharmaceutical Companies of Johnson & Johnson has released efficacy and safety data for STELARA (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC), including data from the SEAVUE study, the first study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session. Read More

#News

#AstraZeneca #Clinical trials #Covid-19 #Moderna #Pfizer #Research

Behind the UK Cov-Boost trial

The UK government has begun the Cov-Boost clinical trials for a booster coronavirus vaccine in a bid to test its effectiveness against the new variants of the virus. As part of the trial, seven vaccines ordered by the UK government will be tested on thousands of volunteers at random… Read More

#Covid-19 #Exclusive Content #News

#Biotherapeutics #Cardiovascular disease #Clinical trials #mRNA #Therapeutics

Positive data from study of siRNA in iron-loading anaemia conditions

Silence Therapeutics and Nasdaq have announced positive topline data from the GEMINI Phase I study of its wholly owned product candidate, SLN124, in healthy volunteers. SLN124, an siRNA which targets TMPRSS6, is in development for the treatment of iron-loading anaemia conditions, thalassemia and myelodysplastic syndrome (MDS). The GEMINI Phase I,… Read More

#News

Patient receiving vaccine
#Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Vaccines

Sanofi and GSK Covid-19 vaccine to progress to Phase III trials

The Sanofi and GSK adjuvanted recombinant Covid-19 vaccine candidate achieved strong rates of neutralising antibody responses, in line with those measured in people who have recovered from Covid-19, in all adult age groups in a Phase II study with 722 volunteers. The Phase II interim results showed 95% to 100%… Read More

#Covid-19 #News #Trending News

#Clinical trials #Database #Drug development #Research

Clinical trials database will save researchers time and resources

The National Institute for Health Research’s Innovation Observatory (NIHRIO), based at Newcastle University, has launched a comprehensive database of clinical trials as well as FDA-approved medical devices, diagnostics and digital applications. Designed as a free resource, researchers can access information about what research is in progress in their area… Read More

#News